9th Jan 2006 15:32
Allergy Therapeutics PLC09 January 2006 Allergy Therapeutics plc ("the Company") The Company received notification on 6 January 2006 that Fidelity InternationalLimited ("FIL") and its direct and indirect subsidiaries, including FidelityInvestment Services Ltd ("FISL"), Fidelity Gestion (FIGEST), FidelityInvestments Advisory (Korea) Limited (FIA(K)L), Fidelity Investments Management(Hong Kong) Limited (FIMHK), Fidelity Pension Management ("FPM") and FidelityInvestments International (FII), investment managers for various non-USinvestment companies and institutional clients, are together interested in atotal of 6,862,044 ordinary shares in the Company, representing approximately10.90 per cent. of the Company's issued share capital. This shareholding is registered as follows: Shares held Management Nominee/Registered Name Company 1,231,500 FPM Northern Trust London 484,300 FPM Mellon Bank 478,800 FPM JP Morgan 438,062 FPM Bank of New York Brussels 381,484 FPM State Str Bk and TR Co LDDN 232,200 FPM Bankers Trust 121,100 FPM Midland Securities Services 78,700 FPM Clydesdale Bank plc 2,958,398 FISL JP Morgan 330,400 FIL Brown Bros Harrimn Ltd Lux 118,700 FIL Bank of New York Brussels 8,400 FIL JP Morgan 6,862,044 Total holding This notifiable interest also comprises the notifiable interest of Mr Edward C.Johnson III, a principal shareholder of Fidelity International Limited, andinterests held on behalf of authorised unit trust schemes in the United Kingdom. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Allergy Thera.